AgomAb Therapeutics NV (AGMB) Discusses Open-Label Extension Results of Phase IIa ...
Fibrostenosing (stricturing) Crohn’s disease is a major cause of complications and surgeries. Early-phase clinical results about a therapy targeting fibrotic strictures could matter to people facing strictures or...